Latest Investigation News

Straker Limited resumes ASX trading after suspending shares due to transaction anomalies at its US subsidiary. The company maintains normal operations while cooperating with US authorities.

Neurizon Therapeutics has boosted the participant count in its HEALEY ALS Platform Trial Regimen I from 160 to 240, capitalising on faster enrolment and philanthropic support to maintain costs and accelerate topline results to early Q3 2027.

Rural Funds Group has lodged replacement constitutions for its key trusts, Rural Funds Trust and RF Active, refining governance, stapling mechanics, and compliance frameworks to align with evolving regulatory standards.

Skin Elements Limited has lodged an application with the Takeovers Panel alleging undisclosed voting power exceeding 20% via a private placement, raising questions about shareholder rights ahead of critical board spill meetings.

Altitude Minerals has locked in a 2,300m drilling permit and contracted a rig to test high-priority copper-gold targets at its Byrock Project in NSW, with drilling set to start mid-June 2026.

Dalaroo Metals gears up for its largest and most integrated exploration program at Blue Lagoon, combining onshore and offshore techniques to probe critical minerals in southern Greenland.

Tarrina Resources has expanded the known gold anomaly at its Christmas Gift Gold Project by over a kilometre, unveiling 29 new soil geochemical targets including 12 high priorities that could reshape exploration plans.

White Energy has inked a non-binding term sheet to acquire coal assets in Alabama and Queensland, backed by a $15 million capital raise and planned board reshuffle.

Tuas Limited has called off its planned acquisition of M1 Limited after failing to meet critical conditions by the extended deadline, while regulatory scrutiny intensifies around its subsidiary Simba Telecom.

Strata Minerals’ Phase 2 drilling at Zelica confirms consistent shallow high-grade gold over a 1km strike, revealing new plunging shoots and a hanging-wall lode that could expand the system across a 9.5km corridor.

Strategic Elements Limited is raising up to $1 million via a Share Purchase Plan (SPP) at 3.5 cents per share, with attaching options exercisable at 4 cents, to fuel development in Energy Ink™ and Stealth Technologies.

Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.